Elicio Therapeutics, Inc. Restricted Cash, Current
Elicio Therapeutics, Inc. (ELTX) had Restricted Cash, Current of $0 as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:RestrictedCashCurrent · last filed 2026-03-12
- 2025-12-31: Restricted Cash, Current $0.00.
- 2025-09-30: Restricted Cash, Current $0.00.
- 2025-06-30: Restricted Cash, Current $0.00.
- 2025-03-31: Restricted Cash, Current $683.00K.
| Period end | Restricted Cash, Current |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 |
| 2025-03-31 | $683.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $1.18M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.32M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $396.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $665.00K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $722.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.67M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-14 |
| 2022-12-31 | $1.64M 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |